Fractyl Health (GUTS) Income from Continuing Operations (2023 - 2026)
Fractyl Health's (GUTS) quarterly Income from Continuing Operations came in at 26134000.0 in Q1 2026, up 67.71% YoY from 15583158.1 in Q1 2025, and down 10.16% on a QoQ basis from 23723000.0 in Q4 2025.
Fractyl Health (GUTS) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Income from Continuing Operations data on file, last reported at 26134000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 67.71% year-over-year to 26134000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 207233000.0 (up 23.66% YoY) and the FY2025 annual result came in at 243455000.0, down 16.37% from the prior year.
- Income from Continuing Operations slipped to 26134000.0 in Q1 2026, from 23723000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11690000.0 in Q1 2023 to a low of 82528000.0 in Q2 2024.
- A 4-year average of 42690769.23 and a median of 26082000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 604.1% — and 2026, when it soared 67.71%.
- Tracing GUTS's Income from Continuing Operations over 4 years: stood at 13130000.0 in 2023, then tumbled by 95.12% to 25619000.0 in 2024, then climbed by 7.4% to 23723000.0 in 2025, then slipped by 10.16% to 26134000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 26134000.0 (Q1 2026), 23723000.0 (Q4 2025), and 76301000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | -18.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.99 Mn |
| Mar 31, 2026 | -26.13 Mn |
| Dec 31, 2025 | -23.72 Mn |
| Sep 30, 2025 | -76.30 Mn |
| Jun 30, 2025 | -81.08 Mn |
| Mar 31, 2025 | -80.93 Mn |
| Dec 31, 2024 | -25.62 Mn |
| Sep 30, 2024 | -82.40 Mn |
| Jun 30, 2024 | -82.53 Mn |
| Mar 31, 2024 | -26.08 Mn |
| Dec 31, 2023 | -13.13 Mn |
| Sep 30, 2023 | -13.65 Mn |
| Jun 30, 2023 | -11.72 Mn |
| Mar 31, 2023 | -11.69 Mn |